Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III open-label titration trial of testosterone [Natesto] twice daily patients with hypogonadism

Next Previous
X
Search
Trial Profile

Phase III open-label titration trial of testosterone [Natesto] twice daily patients with hypogonadism

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acerus Pharmaceuticals

    • Most Recent Events

    • 07 Aug 2015 New trial record
    • 05 Aug 2015 Dosing is expected to be initiated within the coming weeks with trial completion anticipated by the end of first quarter of 2016, according to a Trimel Pharmaceuticals Corporation media release.
    • 05 Aug 2015 According to a media release, Trimel Pharmaceuticals Corporation has completed the protocol for this trial. The investigator sites have been selected and trained, and screening for patients that meet the inclusion-exclusion criteria has started.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top